Antibody Drug Conjugates in Bladder Cancer: Current Milestones and Future Perspectives

Area of Science:

• Urothelial Carcinoma Treatment
• Oncology
• Pharmacology

Background:

• The treatment landscape for urothelial carcinoma has rapidly evolved.
• New therapeutic classes, including antibody drug conjugates (ADCs), have emerged.
• Early data suggests ADCs offer safety and efficacy in various stages of bladder cancer.

Purpose of the Study:

• To review the emerging role of antibody drug conjugates (ADCs) in urothelial carcinoma treatment.
• To highlight specific ADCs like enfortumab-vedotin (EV), sacituzumab-govitecan (SG), and oportuzumab monatox (OM).
• To discuss the potential of ADCs as a mainstay therapy in urothelial carcinoma management.

Main Methods:

• Review of recent clinical trial data and cohort studies.
• Analysis of therapeutic options including checkpoint inhibitors, tyrosine kinase inhibitors, and ADCs.
• Evaluation of safety and efficacy profiles of specific ADCs in urothelial carcinoma.

Main Results:

• Enfortumab-vedotin (EV) demonstrated effectiveness as neoadjuvant monotherapy and in combination with pembrolizumab.
• Other ADCs, such as sacituzumab-govitecan (SG) and oportuzumab monatox (OM), also show promising results.
• ADCs represent a potentially safer and effective treatment modality in both early and advanced urothelial carcinoma.

Conclusions:

• Antibody drug conjugates (ADCs) are likely to become a cornerstone of urothelial carcinoma treatment.
• ADCs may be utilized as monotherapy or in combination regimens.
• The cost of ADCs requires further evaluation, but clinical data supports their potential as a mainstay treatment.